Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.
Annice HeratizadehE HaufeD StölzlS AbrahamL HeinrichA KleinheinzAndreas WollenbergE WeisshaarMatthias AugustinF WiemersAlexander ZinkR von KiedrowskiM HilgersM WormM PawlakM SticherlingI FellC HandrickK SchäkelP Staubach-RenzA AsmussenB SchwarzM BellI EffendyT BieberB HomeyB GerlachE TchitcherinaM StahlU SchwichtenbergJ RossbacherP BuckM MempelS BeissertT BiedermannS WeidingerJ SchmittT Werfelnull nullPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
These 'real-life' data clearly demonstrate the substantial disease burden. Most of TREATgermany patients were already treated with or prescribed dupilumab at baseline. Moreover, current findings indicate the urgent need for further alternative agents in order to achieve a perceptible improvement of quality of life of patients with moderate-to-severe AD.